Key result
Sotatercept advances PAH treatment as a landmark therapy targeting activin pathways for reverse remodeling.
Why the study?
Despite improved outcomes with treatments targeting three main pathways, there remains a critical need for novel therapies addressing different mechanisms of pulmonary arterial hypertension.
Does sotatercept improve outcomes in adult PAH patients with WHO functional class II or III symptoms on background therapy?
Does sotatercept improve outcomes in adult PAH patients with WHO functional class II or III symptoms on background therapy?
Sotatercept represents a landmark advancement in PAH treatment by targeting reverse remodeling in the pulmonary vasculature and right ventricle.
Answers are grounded in this paper and cite their sources.
Highlights potential for disease-modifying PAH therapy; leaves open confirmation of clinical benefit in randomized settings.
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by proliferative remodeling and obliterative narrowing of the pulmonary vasculature. While outcomes have improved with existing treatments targeting 3 main pathways, there remains a critical need for novel therapies that address different and novel mechanisms of PAH. Sotatercept, recently Food and Drug Administration (FDA) approved, is a groundbreaking fusion protein that binds to activin and growth differentiation factors, rebalancing antiproliferative and pro-proliferative signals to reverse remodeling in both the pulmonary vasculature and the right ventricle. This review highlights current evidence exploring the safety and efficacy of sotatercept in the 2 landmark trials, phase 2 Pulmonary Arterial Hypertension and Sotatercept Trial and Research and phase 3 Sotatercept Treatment in Expansion of Long-term Learning and Assessment in PAH trial, which were instrumental in securing FDA approval for adult PAH patients with WHO functional class II or III symptoms already receiving background pulmonary hypertension therapy. Overall, sotatercept represents a landmark advancement in PAH treatment, offering hope for patients and the potential to delay or avoid lung transplantation. Importantly, this marks the beginning of an era of targeted therapies aimed at reverse remodeling in PAH while improving outcomes.
No takes yet. Share an insight, caveat, or question.
Anand et al. (2025) conducted a review in Pulmonary arterial hypertension (PAH). Sotatercept was evaluated. Sotatercept, a novel fusion protein targeting activin and growth differentiation factors, represents a landmark advancement in pulmonary arterial hypertension treatment aimed at reverse remodeling.
Synapse has enriched 10 related papers. Consider them for comparative context: